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Summary Widely disseminated neuroblastoma in children older than infancy remains a very poor prognosis
disease. Even the introduction of marrow ablative chemotherapy with autologous rescue has not significantly
improved the outlook for these children, presumably because of a failure to eradicate minimal residual disease.
One additional approach which may hold promise is the use ofimmunomodulation with cytokines such as IL2
in the setting of minimal residual disease (MDR), for example after intensive chemotherapy and ABMT.
However, considerable variability in the susceptibility of neuroblastoma cells to natural killer (NK) and
lymphokine-activated (LAK) killing has been observed, and it is presently unclear how NK and LAK cells
recognise neuroblastoma cells. In this paper we examine expression of cell adhesion molecules on neuro-
blastoma to determine which of these modify interaction with NK and LAK cells. We find that LFA-3
(CD58), the ligand for CD2 is of predominant importance in predicting susceptibility of neuroblastoma to the
cytotoxic actions of NK and LAK cells, while expression of ICAM-1 (CD54) may also modify susceptibility.
These findings were confirmed by blocking experiments in which co-culture of target cells with ICAM-1 and
LFA-3 reduced LAK and NK cytotoxicity. Study of the immunophenotypic features of each patient's
neuroblastoma cells before induction of MRD may be valuable in determining the likely effect of IL2 in
predicting disease reactivation.
Neuroblastoma in the child over the age of 2 is disseminated
in over 70% of children at presentation (Hayes & Smith,
1989), usually involves the bone marrow and has an ex-
tremely poor prognosis, with survival rates of under 10%
reported (Look et al., 1991). Attempts to improve the prog-
nosis have been made by giving ablative doses of chemo-
therapy with autologous marrow rescue, once remission is
achieved (Pritchard et al., 1982; Graham-Pole et al., 1991).
However most children still relapse and it is uncertain wheth-
er ABMT is an improvement over conventional therapy
(Anderson & Coccia, 1991; Shuster et al., 1991).
The ability of some infants with widely disseminated
disease to achieve spontaneous cure (D'Angio et al., 1991;
Evans et al., 1981) would suggest that immune mechanisms
may be active in this disease and that stimulation of such
mechanisms might be predicted to increase the probability of
disease eradication. Since neuroblastoma cells have reduced
or absent class I and II antigens (Gross et al., 1990; Favrot et
al., 1990; Favrot et al., 1991), any attempt to stimulate
antitumoral defense should recruit MHC unrestricted im-
munity (Main et al., 1985). Both IL-2 and infusions of LAK
cells have been used in neuroblastoma and tolerated (Nsar et
al., 1989; Negrier et al., 1991). Not surprisingly, in end-stage
neuroblastoma, with extensive disease and involvement of the
bone marrow, there is little or no benefit in this therapy, in
part due to the immunologic impairment of such patients
(Negrier et al., 1991; Reynolds et al., 1989). A more suitable
setting for immunomodulation may be patients following
bone marrow transplantation as children at transplantation
are free of detectable disease but still subsequently relapse.
Disease in these children must recur from a small number of
residual neuroblastoma cells, which may be vulnerable to the
IL-2 responsive NK and LAK cells present after transplanta-
tion (Reittie et al., 1989). Supporting this is the response in
two !out of four neuroblastoma patients treated with IL-2
after ABMT (Negrier et al., 1991).
However, the vulnerability of neuroblastoma cells to NK
and LAK effector mechanisms varies widely (Duan et al.,
1990; Handgretinger et al., 1989). It is unknown why this
variation occurs, but neuroblastoma cells express different
levels of a number of cell adhesion molecules (CAM) and
their ligands (Favrot et al., 1990; Favrot et al., 1991). If
IL2/LAK cells are to be used after ABMT as adjuvant
therapy, it would be valuable to predict whether or not
residual neuroblastoma cells would be susceptible to NK/
LAK cell lysis. We have therefore investigated which
CAM-ligand interactions best determine neuroblastoma cell
susceptibility to NK/LAK lysis.
Materials and methods
Neuroblastoma cell lines
Eleven cell lines were derived in our institution from the
involved bone marrows ofchildren with neuroblastoma. Nine
out of eleven of these lines were derived from tumours with
amplified n-myc and amplification was maintained in in vitro
culture (Brodeur et al., 1988). Amplification of n-myc is a
poor prognostic feature in neuroblastoma. Seven of these 11
lines had a normal tumour cell DNA content (D.I. of 1);
again a poor prognostic feature (Look et al., 1991).
Immunophenotyping
Immunophenotyping was performed using the methods
previously described (Campana et al., 1990). Antibodies used
were LFA-1 alpha subunit (CD1 Ia, AMAC, Inc, Westbrook,
ME), LFA-2 (CD2, from hybridoma cell line HB 195,
ATCC, Rockville, MD), LFA-3 (CD58, from hybridoma cell
line HB 205, ATCC), VLA-2 (CD49b), VLA-4 (CD49d,
AMAC), VLA-6 (CD 49f, AMAC), ICAM (CD54, AMAC),
NCAM (CD56, AMAC), and GD-2 (from hybridoma cell
line HV 8568, ATCC). Positivity was assessed by fluorescence
microscopy (Zeiss, Germany), by an investigator blinded to
the results of the NK and LAK lysis assays. Fluorescence
microscopy was used instead of FACS analysis because of
variable and unpredictable neuroblastoma cell clumping dur-
ing flow cytometry.
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Natural killer and lymphokine-activated killer cell cultures
To minimise potential variability in cytotoxicities from
peripheral blood effectors derived from different individuals a
single donor was used. Heparinised blood was collected from
a normal donor and diluted 1:1 with RMPI 1640 medium
(Flow Laboratories, McLean, VA). The blood was layered in
20 ml aliquots on 20 ml Lymphocyte Separation Medium
(Organon Teknika, Durham, NC). After centrifugation at
1,900 r.p.m. (404g) for 30 min at room temperature, inter-
face mononuclear cells were collected and washed twice in
RPMI. They were then resuspended at a concentration of
2.5 x 106 cells per ml in RPMI containing 10% heat inac-
tivated foetal calf serum (Whittaker, Walkerville, MD), and
supplemented with L-glutamine (Whittaker) and penicillin/
streptomycin (Whittaker). Cells were incubated overnight in
this medium with (LAK cells) and without (NK cells) recom-
binant human IL-2 (Cetus) at 1,000IUml-'.
Chromium release assays
Four hour 5"chromium release assays were used to measure
the susceptibility of the different neuroblastoma lines to NK
and LAK cytotoxicity. Target neuroblastoma cells were
labelled by incubation at 37°C with 150 microCi of
Na251CrO4 (Amersham, Aylesbury, UK) for 90 min in 0.3 ml
ofmedium. The cells were then washed twice and diluted to a
viable cell count of 5 x I04. They were incubated with the
effector cells (NK and LAK cells) at ratios of effectors to
target of 50:1, 25:1, 12:1 and 6:1 in v-bottomed microtiter
plates (Costar, Cambridge, MA). After 4 h of incubation at
37°C in 5% C02, the culture supernatants were harvested
and counted in a gamma counter.
Maximal release of the incorporated 5'Cr into target
neuroblastoma cells was measured by lysis of these cells by
Triton X-100 (Signam, St Louis, MO). Spontaneous release
was measured by counting supernatant of labelled cells
incubated in medium only. All testing was done in triplicate.
All cell lines were tested for killing by NK and LAK cells
twice to four times. Another three volunteer donors were
used to ensure that the cytotoxicity seen against neuroblas-
tomas was not unique to the one volunteer donor. Similar
ratios of killing between different neuroblastomas were seen
with the other volunteer donors, but these experiments were
regarded as confirmatory and were not repeated.
The results were expressed as
percentage lysed
experimental c.p.m. - spontaneous c.p.m.
maximum - spontaneous chromium release
Spontaneous release of 51Cr ranged from 3 to 20% of max-
imum.
Blocking assays
For the blocking experiments, target cells at 5 x 104ml-'
were incubated with either VLA-4,ICAM-1 (CD54), LFA-1
(CDlla), or LFA-3 (CD58) antibody for 30min, immed-
iately following incubation with 51Cr. Three concentrations,
0, 2.5 and 10 Igml-', of antibody were used for VLA-4,
ICAM-1 and LFA-1, while for LFA-3, the cells were
incubated either in medium alone or in the hybridoma super-
natant. AD control mouse IgG was added at the same
concentration. After incubation, the cells were washed twice.
These antibody treated cells were then used as targets for NK
and LAK cells as previously.
Results
NK and LAK cell susceptibility of the neuroblastoma cell
lines varied considerably (Figure 1). In all, however, LAK
mediated lysis measured in the Cr-release assays was con-
siderably greater than NK killing. All but one neuroblastoma
line were strongly positive for GD2 and NCAM, while all
were negative for LFA-1 and LFA-2. Expression of LFA-3,
ICAM-1, VLA-2, VLA-4 and VLA-6, however, was more
variable (shown graphically in Figure 2).
To determine if NK or LAK susceptibility was correlated
with expression of any cellular adhesion molecule (CAM) or
ligand, percentage killing vs CAM/ligand expression was
plotted for each line. No correlation can exist between
susceptibility to killing and the expression of cell adhesion
molecules LFA-1, LFA-2, GD2 or the ligand NCAM, but
although levels of VLA 2, 4 and 6 expression varied between
cell lines, no correlation was seen between expression of these
structures and NK or LAK killing. However, statistically
significant correlations were seen between the expression of
LFA-3 (the ligand for CD2) and NK and LAK killing
(Figures 3a, b). A backward stepwise model was used to
assess the ability for each of LFA-3, ICAM-1, VLA-2, VLA-
4 and VLA-6 to predict LAK. A backward stepwise model
first includes all predictor variables in the model, and in a
stepwise fashion deletes one variable at a time until only
statistically significant predictor variables remain. The result
in the analyses using LAK as the dependent variable was
that LFA-3 was the only significant (P= 0.018) predictor
variable. Now, the supporting evidence for the significance of
LFA-3 as a predictor of LAK is that LFA-3 when adjusted
for a model containing all other antibodies except VLA-4
remains significant (P<0.05).
Although LFA-3 is a significant predictor variable for NK
killing (P = 0.026) when considered alone, its predictive
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Figure 1 Shows percentage lysis with the LAK and NK cells as effectors for the different cell lines. Cell lines are ranked in order
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ability in the presence of other antibodies is diminished. A
backward stepwise analysis, similar to that for LAK des-
cribed above, results in a model containing both ICAM-1
(P = 0.08) and VLA-4 (P = 0.03). The overall model is
significant (P = 0.04, r2 = 0.55). These results may depend on
the extreme variability (high standard deviation) of the data.
Note that there is a significant correlation between LFA-3
and ICAM-l (Spearman's r = 0.60, P = 0.05).
As noted, the standard deviation exhibited by each of the
antibodies is high. This led to a variance stabilising-analysis
in which the natural logarithm of both the dependent and
independent variables were taken and another regression
analysis performed. The result of the backward stepwise
regression for LN(LAK) indicates that LFA-3 is significant
(P = 0.04) even in the presence of (when adjusted for) the
four other antibodies. The final model includes only
LN(LFA-3) (P<0.01, r2 = 0.65). Performing a similar
analysis for LN(NK), LN(LFA-3) is significant when
adjusted for all other antibodies except LN(ICAM-1). Again,
this is probably due to power. The final model contains only
LN(LFA-3) (P<0.01, r2 = 0.66).
To further establish the relevance of CAM expression to
cytotoxic vulnerability, neuroblastoma cell lines were incub-
ated with blocking antibodies prior to co-culture with
effector cells. No blocking of NK and LAK killing was seen
with LFA-1 or VLA-4, but after incubation with ICAM-1,
eight out of eleven neuroblastoma lines showed a mean
reduction of30% (range 17-52%) (t-test, P<0.005) in LAK
killing, at an effector:target ratio of 25:1 (Figure 4). Five out
of these eight lines also showed reduction in NK killing with
ICAM-1. Blocking was maximal with 2.5fgml-' and not
further blocking was seen with 10 gml-'. Similarly, LFA-3
reduced LAK killing in seven out of nine lines tested, by a
mean of 41% (range 30-76%) (t-test, P<0.005) (Figure 5).
LFA-3 also reduced NK killing in five of these seven lines.
There was no significant blocking with either LFA-1 or
VLA-4.
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Figure 4 Percentage reduction in LAK mediated cytotoxicity for eight neuroblastoma cell lines by anti-ICAM-l.
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Figure 5 Percentage reduction in LAK mediated cytotoxicity for seven neuroblastoma lines by anti-LFA-3.
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Discussion
We have shown that the variable sensitivity ofneuroblastoma
cells to MHC unrestricted killing appears to correlate with
variation in their expression of cell adhesion molecules. Cell
adhesion molecules are members of the immunoglobulin and
integrin supergene families, whose extra-cellular domains par-
ticipate both in the process of cell adhesion to extra-cellular
proteins, and in cell-to-cell adhesion and interaction (Sim-
mons et al., 1988; Kishimoto et al., 1987). These molecules
are integral to immune recognition and may play a role in
host recognition of transformed cells (Dustin et al., 1987;
Makgoba et al., 1989; Sanders et al., 1988). We examined a
number of cellular adhesion molecules and their ligands,
including those previously described as present on neuroblas-
toma cells and those known to be important in MHC unrest-
ricted killing (Favrot et al., 1990; Favrot et al., 1991; Gross
et al., 1991; Timonen, 1990; Oblakowski et al., 1991).
We found marked differences in the ability ofeach of these
molecules to predict the MHC unrestricted cytotoxic suscep-
tibility of neuroblastoma cells. We confirmed that GD2 and
NCAM are commonly and strongly expressed by neuroblas-
toma cells, so that variation in their expression would not
account for differences in cytotoxic susceptibility. The VLA
antigens were of greater potential interest. Not only does
their expression vary between tumour cell lines, but VLA-4
has been reported to be required for cell-mediated lysis of
melanoma, another tumour derived from neural crest cells
(Anichini et al., 1990). However, no correlation was found
between expression of VLA-4 and susceptibility to NK/LAK
lysis and antibody to VLA-4 had no effect on the suscep-
tibility of neuroblastoma lines to cytotoxic effector cells. The
VLA receptor ligand system is not therefore of generic
importance in interactions of neural crest-derived tumour
cells with effector cells of the immune system.
Of all the receptor-ligand systems studied, only LFA-3 (the
ligand for LFA-2) and ICAM-1 (the ligand for LFA-1) could
be shown to be important in determining susceptibility to
MHC unrestricted lysis. Thus, the percentage expression of
LFA-3 correlated with cytotoxic susceptibility and the two
lines that were least susceptible to killing were both <1%
ICAM-l positive. The data also imply that only low levels of
ICAM-l expression are required to achieve the maximum
susceptibility conferred by this ligand, since it was only at the
lowest levels of expression that this molecule appeared to
influence the vulnerability of the target cell line.
The importance of LFA-3 and ICAM-1 expression in
determining the susceptibility to lysis was confirmed by
blocking studies. The majority of the lines tested showing
substantial blocking with each antibody. The ability of anti-
ICAM-1 monoclonal antibody to block lysis also excludes
the possibility that ICAM-1 iteself predicted susceptibility to
NK/LAK lysis only because it is co-expressed with LFA-3.
Whether or not this study is relevant to assessing the
NK/LAK sensitivity of fresh tumour cells depends on wheth-
er ligand expression in vivo is similar to that of the neurob-
lastoma cell lines studied. ICAM-1 expression in clinical
specimens at diagnosis has been shown to be restricted to a
minority of neuroblastomas. Intriguingly, however, this
subset of tumours has a favourable outlook, further suppor-
ting the concept that expression of ligands for cell adhesion
molecules may determine susceptibility to immune system
clearance mechanisms, and improve prognosis. Similarly,
LFA-3 was expressed in vivo in only a minority of low stage,
well differentiated, good prognosis tumours (Favrot et al.,
1991). LFA-3 expression can also be induced in vivo - even in
some high stage undifferentiated tumours - by chemotherapy
(Favrot et al., 1991). If LFA-3 and ICAM-1 do indeed confer
susceptibility to NK/LAK killing then assessment of tumour
susceptibility might most appropriately be made after
exposure to chemotherapy and a decision then made as to
whether it was appropriate to progress to ABMT and/or
therapy with immunostimulators such as IL2. Finally, it will
be of interest to discover whether expression of cell adhesion
molecules modifies MHC restricted, antigen specific, T cell
killing of neuroblastoma cells, if such killing exists (Brenner
et al., 1992).
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